The company posted a net profit of 668 million rupees ($8.06 million) for the quarter ended Dec. 31, compared to a loss of 156 million rupees a year ago.

The Noida-based firm's total revenue rose 8% to 16.77 billion rupees, with its radiopharma business - which involves developing radioactive medications used to diagnose or treat cancer - making up more than 40% of the total. The segment grew 22.7% during the quarter.

This is the fifth straight quarter that the company's revenue has risen. Jubilant Pharmova is involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the U.S. The company's future revenue will be driven by its high-margin radiopharmaceuticals division, according to analysts. Shares of Jubilant Pharmova rose as much as 7% after the results, hitting a more than two-year high.

($1 = 82.8630 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru; Editing by Sonia Cheema)